Trifluridine
Approved · EMAAlso known as 5-(Trifluoromethyl)deoxyuridine, 5-Trifluoromethyl-2-deoxyuridine, Lonsurf, TFT+7 more
5-(Trifluoromethyl)deoxyuridine, 5-Trifluoromethyl-2-deoxyuridine, Lonsurf, TFT, Trifluoromethyldeoxyuridine, Trifluorothymidine, Trifluorothymine deoxyriboside, Viroptic, Trifluridin, Trifluridina, Trifluridinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior… Show full indicationShow less
Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents Gastric cancer Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes7
Journals, researchers & institutions
- ESMO open1
- JAMA network open1
- The New England journal of medicine1
- Ciardiello F2
- Cremolini C2
- Akashi K1
- Amellal N1
- Avallone A1
- Baba E1
- Bardelli A1
- Benhadji KA1
- Azienda Ospedaliero-Universitaria Pisana1
- Comprehensive Cancer Center1
- European Institute of Oncology1
- Experimental Clinical Abdominal Oncology Unit1
- Graduate School of Medical Sciences1
- IFOM ETS-The AIRC Institute of Molecular Oncology1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Trifluridine in the shared literature.
Studied across 5 of the same disease areas as Trifluridine in the shared literature.
Studied across 4 of the same disease areas as Trifluridine in the shared literature.
Studied across 4 of the same disease areas as Trifluridine in the shared literature.
Studied across 3 of the same disease areas as Trifluridine in the shared literature.
Studied across 3 of the same disease areas as Trifluridine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.